Method for treating bladder cancer
A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
1. A method for treating bladder cancer, comprising the step(s) of:
administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by bladder cancer, wherein the protonated form of the surfactant is represented by the following chemical structure:
wherein R 1 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; wherein R 2 comprises NCS; and wherein R 3 -R 5 are the same or different and comprise H; OH; an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer with the proviso that at least one of R 3 -R 5 comprise an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 8 to approximately 25 carbon atom(s).
2. A method for treating bladder cancer, comprising the step(s) of:
administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by bladder cancer, wherein the protonated form of the surfactant is represented by the following chemical structure:
wherein X comprises an integer ranging from approximately 1 to approximately 25, and wherein Y comprises an integer ranging from approximately 6 to approximately 25.
3. A method for treating bladder cancer, comprising the step(s) of:
administering a surfactant or a pharmaceutically acceptable salt thereof to an area affected by bladder cancer, wherein the protonated form of the surfactant is represented by the following chemical structure:
4. The method for treating bladder cancer, according to claim 1 , further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.
5. The method for treating bladder cancer, according to claim 1 , wherein the bladder cancer is selected from one of the groups comprising urothelial carcinoma, transitional cell carcinoma, papillary carcinomas, flat carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and sarcoma.
6. The method for treating bladder cancer, according to claim 2 , further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.
7. The method for treating bladder cancer, according to claim 2 , wherein the bladder cancer is selected from one of the groups comprising urothelial carcinoma, transitional cell carcinoma, papillary carcinomas, flat carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and sarcoma.
8. The method for treating bladder cancer, according to claim 3 , further comprising the step of administering an additional surfactant, wherein the additional surfactant is selected from at least one of the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof.
9. The method for treating bladder cancer, according to claim 3 , wherein the bladder cancer is selected from one of the groups comprising urothelial carcinoma, transitional cell carcinoma, papillary carcinomas, flat carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, and sarcoma.